Ep 264 - This Groundbreaking Biotech Developments Are Revolutionizing Cannabis And Beyond - with Cameron Keluche of KelSie Biotech and SUM Microdose
Publisher |
Matthew Kind
Media Type |
audio
Podknife tags |
Business
Interview
Investing
Marijuana
Categories Via RSS |
Business
Investing
Publication Date |
May 19, 2019
Episode Duration |
00:31:53

Incredible biotech developments are starting to bring new and exciting products to the cannabis market that would have seemed like science fiction just a few years ago.

Here to tell us about it is Cameron Keluche, founder and CEO of sublingual cannabis tablet company SUM Microdose and president and CEO of KelSie Biotech, an innovation and intellectual property holding company in Boulder, CO.

In this episode, Cameron shares with us a breakdown of KelSie’s “Bubble Drying” technology and how it’s quickly revolutionizing both the pharmaceutical and cannabis industries.

Learn more at sie.com/">https://www.kel-sie.com and https://www.summicrodose.com

 

Key Takeaways:

  • Cameron Keluche’s personal background and journey in the cannabis space
  • An inside look at KelSie Biotech and SUM Microdose and their mission to bring cannabis into the pharmaceutical market
  • How KelSie Biotech is applying Bubble Drying - the same technology used to create a dry measles vaccine - to formulate the world’s most stable cannabis powder
  • Ways in which KelSie Biotech’s dry cannabis powder can be used as an inhalant for optimal bioavailability
  • An explanation of “excipients” and how they help the body pull in cannabinoids more effectively than oil constituents
  • Ways in which inhalants are superior to other cannabis delivery methods
  • How SUM Microdose uses KelSie Biotech’s Bubble Drying technology to create sublingual cannabis tablets designed for different purposes including mood and sleep
  • Ways in which KelSie and SUM are bridging the gap between the pharmaceutical biotech and cannabis spaces and Cameron’s goals for the years ahead

 

keluche-kelsie-biotech-sum-microdose.jpg" alt="" width="400" height="400">

Incredible biotech developments are starting to bring new and exciting products to the cannabis market that would have seemed like science fiction just a few years ago.

Here to tell us about it is Cameron Keluche, founder and CEO of sublingual cannabis tablet company SUM Microdose and president and CEO of KelSie Biotech, an innovation and intellectual property holding company in Boulder, CO.

In this episode, Cameron shares with us a breakdown of KelSie’s “Bubble Drying” technology and how it’s quickly revolutionizing both the pharmaceutical and cannabis industries.

Learn more at sie.com/">https://www.kel-sie.com and https://www.summicrodose.com

 

Key Takeaways:

  • Cameron Keluche’s personal background and journey in the cannabis space
  • An inside look at KelSie Biotech and SUM Microdose and their mission to bring cannabis into the pharmaceutical market
  • How KelSie Biotech is applying Bubble Drying - the same technology used to create a dry measles vaccine - to formulate the world’s most stable cannabis powder
  • Ways in which KelSie Biotech’s dry cannabis powder can be used as an inhalant for optimal bioavailability
  • An explanation of “excipients” and how they help the body pull in cannabinoids more effectively than oil constituents
  • Ways in which inhalants are superior to other cannabis delivery methods
  • How SUM Microdose uses KelSie Biotech’s Bubble Drying technology to create sublingual cannabis tablets designed for different purposes including mood and sleep
  • Ways in which KelSie and SUM are bridging the gap between the pharmaceutical biotech and cannabis spaces and Cameron’s goals for the years ahead

 

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review